MX2011011114A - Materiales y metodos para utilizar celulas madre de tejido adiposo para tratar una lesion y enfermedad pulmonar. - Google Patents

Materiales y metodos para utilizar celulas madre de tejido adiposo para tratar una lesion y enfermedad pulmonar.

Info

Publication number
MX2011011114A
MX2011011114A MX2011011114A MX2011011114A MX2011011114A MX 2011011114 A MX2011011114 A MX 2011011114A MX 2011011114 A MX2011011114 A MX 2011011114A MX 2011011114 A MX2011011114 A MX 2011011114A MX 2011011114 A MX2011011114 A MX 2011011114A
Authority
MX
Mexico
Prior art keywords
asc
lung
methods
media
stem cells
Prior art date
Application number
MX2011011114A
Other languages
English (en)
Inventor
Keith March
Irina Petrache
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of MX2011011114A publication Critical patent/MX2011011114A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona métodos para tratar a pacientes con una enfermedad pulmonar aguda o crónica o una lesión a los pulmones que incluye una lesión causada por la exposición al humo de cigarrillos, otros irritantes u otra causa de afección pulmonar. Las condiciones típicas que pueden ser tratadas incluyen condiciones que causan una inflamación en los pulmones o la muerte de células endoteliales pulmonares. El tratamiento de otras condiciones tales como función comprometida de la médula ósea y caquexia también puede realizarse por medio de los métodos inventivos dados a conocer en este documento. Estos métodos incluyen poner en contacto las Células Madre de Tejido Adiposo (ASC) o medios acondicionados por el contacto con ASC (ASC-CM) o varios factores secretados por las mismas que incluyen los medios o componentes de los medios con tejido y células pulmonares. En algunos casos, las ASC utilizadas se recolectan del tejido adiposo propio del paciente mientras que en otros casos la fuente es un donador exógeno.
MX2011011114A 2009-04-20 2010-04-20 Materiales y metodos para utilizar celulas madre de tejido adiposo para tratar una lesion y enfermedad pulmonar. MX2011011114A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17091009P 2009-04-20 2009-04-20
PCT/US2010/031808 WO2010123942A2 (en) 2009-04-20 2010-04-20 Materials and methods for using adipose stem cells to treat lung injury and disease

Publications (1)

Publication Number Publication Date
MX2011011114A true MX2011011114A (es) 2012-04-02

Family

ID=43011726

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011114A MX2011011114A (es) 2009-04-20 2010-04-20 Materiales y metodos para utilizar celulas madre de tejido adiposo para tratar una lesion y enfermedad pulmonar.

Country Status (4)

Country Link
US (2) US20120100112A1 (es)
AU (1) AU2010239323A1 (es)
MX (1) MX2011011114A (es)
WO (1) WO2010123942A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2626369A1 (en) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585916B2 (en) * 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
AU2003220424A1 (en) * 2002-03-19 2003-10-08 Advanced Research And Technology Transfer Adipose stromal stem cells for tissue and vascular modification
WO2004042033A2 (en) * 2002-11-01 2004-05-21 The Board Of Trustees Of The Leland Stanford Junior University Circulating stem cells and uses related thereto
JP2007514476A (ja) * 2003-12-29 2007-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺疾患の診断ツール
WO2006074075A2 (en) * 2004-12-30 2006-07-13 Primegen Biotech, Llc Adipose-derived stem cells for tissue regeneration and wound healing
US7423029B1 (en) * 2007-03-23 2008-09-09 Zoltan Laboratories, Llc Compounds to promote regeneration of bone marrow

Also Published As

Publication number Publication date
WO2010123942A2 (en) 2010-10-28
US20160158289A1 (en) 2016-06-09
AU2010239323A1 (en) 2011-12-15
US20120100112A1 (en) 2012-04-26
WO2010123942A3 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
DE602005026724D1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden
IL214373A0 (en) Use of adipose tissue-derived cells in the preparation of a composition for the treatment of cardiovascular diseases
WO2012071526A3 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
Bhattacharya Wound healing through the ages
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
MX365007B (es) Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
HRP20120887T1 (en) Adherent cells from adipose or placenta tissues and use thereof in therapy
MX2009012197A (es) Metodos para tratamiento de ulceras en la piel.
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
MX340185B (es) Células precursoras cd27 1 derivadas de médula ósea para reparación cardíaca.
WO2007056433A3 (en) Methods of treating tissue defects
Lou et al. Analysis of the effectiveness of basic fibroblast growth factor treatment on traumatic perforation of the tympanic membrane at different time points
MX2011011114A (es) Materiales y metodos para utilizar celulas madre de tejido adiposo para tratar una lesion y enfermedad pulmonar.
MX2020002206A (es) Factor de crecimiento de fibroblastos 21 (fgf-21) modificado para usarse en metodos para tratar la esteatohepatitis no alcoholica (nash).
Chen et al. Growth and differentiation of osteoblasts regulated by low-intensity pulsed ultrasound of various exposure durations
WO2008027238A3 (en) Induction of immunosuppression by inhibition of atm
MX2009004962A (es) Metodo para tratar asma, rinitis alergia y trastornos de la piel.
CN106619703A (zh) 一种快速治疗狐臭的中药粉剂
DE602004028876D1 (de) Verfahren zur verwendung regenerativer zellen bei der behandlung von nierenkrankheiten und störungen
TW201614066A (en) Composition for treatment of joint disease and method thereof
PLOS Neglected Tropical Diseases Staff Correction: Left ventricular systolic dysfunction predicted by artificial intelligence using the electrocardiogram in Chagas disease patients–the SaMi-Trop cohort
FR2984725B1 (fr) Utilisation d'une composition cosmetique ou dermocosmetique pour lutter contre les effets du tabac sur la peau
Das et al. CSP7 Mitigates TSE Induced Airway Injury and Susceptibility to Develop Emphysema
Sack et al. Transcutaneous oximetry values in chronic ulcer patients during Hyperbaric treatment at 1.4 ATA compared to 2 ATA.